A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging
18 Years
N/A
Both
Lymphoma
Trial Information
A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging
OBJECTIVES:
I. Assess the feasibility of detection and quantification of differences in the temporal and
spatial distribution of FDG uptake between lesions of HL and DLBCL.
OUTLINE:
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography
scans 60 and 180 minutes after FDG administration.
After completion of study, patients are followed for 24 hours.
Inclusion Criteria:
- Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with
measurable disease by any imaging technique or physical examination.
Exclusion Criteria:
- Pregnant or nursing,
- Uncontrolled diabetes mellitus,
- Active infection,
- Inability to give informed consent or to comply with all study procedures,
- Subjects may be excluded at the discretion of the principal investigator or study
team members.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Amount of lesional FDG uptake (assessed by qualitative assessment, standardized uptake value (SUV), and lesion to background uptake ratios)
Outcome Time Frame:
At 60 and 180 minutes after FDG administration
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
UPCC 21408
NCT ID:
NCT01004718
Start Date:
May 2009
Completion Date:
May 2013
Related Keywords:
- Lymphoma
- Hodgkin Disease
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
Name | Location |
|---|---|
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania 19104-4283 |
